Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients

J Bone Miner Metab. 2021 Sep;39(5):868-875. doi: 10.1007/s00774-021-01226-1. Epub 2021 Apr 13.

Abstract

Purpose: We aimed to investigate the longitudinal changes in bone metabolic markers and bone mineral density (BMD) after starting or switching from bisphosphonate (BP) to romosozumab (ROMO) or denosumab (DENO) therapies over 12 months and to determine predictors that establish associations with changes in BMD among the patients received the ROMO therapy.

Methods: Postmenopausal osteoporosis patients with a high risk of fracture-154 in total-were recruited; their therapies were switched to ROMO or DENO from BP/naïve or vitamin D (ND) (ND-ROMO: 43, BP-ROMO: 38, ND-DENO: 38, and BP-DENO: 35). Longitudinal changes in bone metabolic markers and BMD were evaluated.

Results: ROMO groups showed significant increases in BMD of the lumbar spine at 6 and 12 months and femoral neck at 12 months compared to the DENO groups. Although BP-ROMO showed significant increase in the lumbar spine BMD compared to BP-DENO, there were no significant differences in femoral neck and total hip BMDs between BP-ROMO and BP-DENO. Among the ROMO groups, % changes of BMD from baseline to 12 months were associated with bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months.

Conclusions: ROMO continuously increased BMD for 12 months and performed better than DENO. On the other hand, effects of ROMO switched from BP on BMD of femoral neck and total hip were almost same with DENO. Bone metabolic markers at baseline and changes in TRACP-5b from baseline to 3 months may predict the efficacy of ROMO after 12 months of administration.

Keywords: Bone metabolic marker; Denosumab; Postmenopausal osteoporosis; Romosozumab.

MeSH terms

  • Antibodies, Monoclonal
  • Bone Density
  • Bone Density Conservation Agents* / therapeutic use
  • Denosumab / therapeutic use
  • Diphosphonates / therapeutic use
  • Female
  • Humans
  • Japan
  • Osteoporosis, Postmenopausal* / drug therapy
  • Postmenopause

Substances

  • Antibodies, Monoclonal
  • Bone Density Conservation Agents
  • Diphosphonates
  • romosozumab
  • Denosumab